Table 1.
Correlation of PVT-1 expression to clinicopathologic features in PDAC
| PVT1 | Χ2 | P | ||
|---|---|---|---|---|
| Low | High | |||
| Sex | 2.143 | 0.143 | ||
| Male | 9 | 6 | ||
| Female | 5 | 10 | ||
| Age | ||||
| <65 | 10 | 10 | 0.268 | 0.605 |
| ≥65 | 4 | 6 | ||
| Lymph node metastasis | 8.438 | 0.004* | ||
| No | 10 | 3 | ||
| Yes | 4 | 13 | ||
| pTNM stage | 3.846 | 0.050 | ||
| I+II | 13 | 10 | ||
| III+IV | 1 | 6 | ||
| Differentiation | ||||
| Well | 5 | 1 | 4.152 | 0.125 |
| Moderate | 6 | 9 | ||
| Poor | 3 | 6 | ||
| Tumor size(cm) | 3.772 | 0.052 | ||
| <3 | 11 | 7 | ||
| ≥3 | 3 | 9 | ||
Values of P were calculated by the Spearman's rank-correlation test. pTNM stage refers to the pathological tumor node metastasis (pTNM) stage designed jointly by the UICC (Union Internationale Against Cancer) and the AJCC (American Joint Committee on Cancer) in 2018. * Statistically significant (P < 0.05).